{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:21:51Z","timestamp":1772061711172,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27350-w","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T09:51:42Z","timestamp":1764928302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics"],"prefix":"10.1038","volume":"15","author":[{"given":"Karen","family":"Matar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmita","family":"Indurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari","family":"Yordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie L.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justis P.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"3","key":"27350_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/DC11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau, J. W. Y. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 35(3), 556\u2013564. https:\/\/doi.org\/10.2337\/DC11-1909 (2012).","journal-title":"Diabetes Care"},{"issue":"3","key":"27350_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/J.OPHTHA.2008.10.016","volume":"116","author":"R Klein","year":"2009","unstructured":"Klein, R. et al. The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 116(3), 497. https:\/\/doi.org\/10.1016\/J.OPHTHA.2008.10.016 (2009).","journal-title":"Ophthalmology"},{"key":"27350_CR3","doi-asserted-by":"publisher","unstructured":"Lee, R., Wong, T. Y. & Sabanayagam, C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2(1):17. https:\/\/doi.org\/10.1186\/S40662-015-0026-2 (2015).","DOI":"10.1186\/S40662-015-0026-2"},{"key":"27350_CR4","unstructured":"Eye Diseases & Conditions: Diabetic Macular Edema (DME). Prevent Blindness. Accessed November 8, 2021. https:\/\/preventblindness.org\/diabetic-macular-edema-dme\/"},{"issue":"12","key":"27350_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/J.ORET.2019.06.010","volume":"3","author":"JP Ehlers","year":"2019","unstructured":"Ehlers, J. P. et al. Higher-Order assessment of OCT in diabetic macular edema from the VISTA study: ellipsoid zone dynamics and the retinal fluid index. Ophthalmol. Retina. 3(12), 1056\u20131066. https:\/\/doi.org\/10.1016\/J.ORET.2019.06.010 (2019).","journal-title":"Ophthalmol. Retina"},{"issue":"3","key":"27350_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/BJOPHTHALMOL-2015-307105","volume":"100","author":"Y Itoh","year":"2016","unstructured":"Itoh, Y., Vasanji, A. & Ehlers, J. P. Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography. Br. J. Ophthalmol. 100(3), 295\u2013299. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2015-307105 (2016).","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"27350_CR7","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1364\/BOE.9.001545","volume":"9","author":"FG Venhuizen","year":"2018","unstructured":"Venhuizen, F. G. et al. Deep learning approach for the detection and quantification of intraretinal cystoid fluid in multivendor optical coherence tomography. Biomed. Opt. Express. 9(4), 1545. https:\/\/doi.org\/10.1364\/BOE.9.001545 (2018).","journal-title":"Biomed. Opt. Express"},{"issue":"7","key":"27350_CR8","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1167\/IOVS.08-2691","volume":"50","author":"AH Kashani","year":"2009","unstructured":"Kashani, A. H., Keane, P. A., Dustin, L., Walsh, A. C. & Sadda, S. R. Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 50(7), 3366\u20133373. https:\/\/doi.org\/10.1167\/IOVS.08-2691 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"27350_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/TVST.6.2.7","volume":"6","author":"MJ Allingham","year":"2017","unstructured":"Allingham, M. J. et al. A quantitative approach to predict differential effects of anti-VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema: A pilot study. Transl Vis. Sci. Technol. 6(2), 7. https:\/\/doi.org\/10.1167\/TVST.6.2.7 (2017).","journal-title":"Transl Vis. Sci. Technol."},{"key":"27350_CR10","doi-asserted-by":"publisher","unstructured":"Li, B., Zhang, B., Chen, Y. & Li, D. Optical coherence tomography parameters related to vision impairment in patients with diabetic macular edema: A quantitative correlation analysis. J. Ophthalmol. 2020, 5639284. https:\/\/doi.org\/10.1155\/2020\/5639284 (2020).","DOI":"10.1155\/2020\/5639284"},{"issue":"12","key":"27350_CR11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/J.ORET.2021.02.012","volume":"5","author":"JP Ehlers","year":"2021","unstructured":"Ehlers, J. P. et al. Longitudinal assessment of ellipsoid zone integrity, subretinal hyperreflective material, and subretinal pigment epithelium disease in neovascular age-related macular degeneration. Ophthalmol. Retina. 5(12), 1204\u20131213. https:\/\/doi.org\/10.1016\/J.ORET.2021.02.012 (2021).","journal-title":"Ophthalmol. Retina"},{"key":"27350_CR12","doi-asserted-by":"publisher","unstructured":"Kessler, L. J., Auffarth, G. U., Bagautdinov, D. & Khoramnia, R. Ellipsoid zone integrity and visual acuity changes during diabetic macular edema therapy: A longitudinal study. J Diabetes Res. 2021, 8117650. https:\/\/doi.org\/10.1155\/2021\/8117650 (2021).","DOI":"10.1155\/2021\/8117650"},{"issue":"12","key":"27350_CR13","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/IJO.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"Browning, D. J., Stewart, M. W. & Lee, C. Diabetic macular edema: Evidence-based management. Indian J. Ophthalmol. 66(12), 1736\u20131750. https:\/\/doi.org\/10.4103\/IJO.IJO_1240_18 (2018).","journal-title":"Indian J. Ophthalmol."},{"issue":"6","key":"27350_CR14","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/J.OPHTHA.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells, J. A. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123(6), 1351\u20131359. https:\/\/doi.org\/10.1016\/J.OPHTHA.2016.02.022 (2016).","journal-title":"Ophthalmology"},{"issue":"11","key":"27350_CR15","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/J.OPHTHA.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier, J. S. et al. Intravitreal Aflibercept for diabetic macular edema: 148-Week results from the VISTA and VIVID studies. Ophthalmology 123(11), 2376\u20132385. https:\/\/doi.org\/10.1016\/J.OPHTHA.2016.07.032 (2016).","journal-title":"Ophthalmology"},{"issue":"12","key":"27350_CR16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/JAMAOPHTHALMOL.2016.3698","volume":"134","author":"LM Jampol","year":"2016","unstructured":"Jampol, L. M., Glassman, A. R., Bressler, N. M., Wells, J. A. & Ayala, A. R. Anti-vascular endothelial growth factor comparative effectiveness trial for diabetic macular edema: Additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmol. 134(12), 1429\u20131434. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2016.3698 (2016).","journal-title":"JAMA Ophthalmol."},{"key":"27350_CR17","doi-asserted-by":"publisher","unstructured":"Furino, C., Boscia, F., Reibaldi, M. & Alessio, G. Intravitreal therapy for diabetic macular edema: An update. J. Ophthalmol. 2021, 6654168. https:\/\/doi.org\/10.1155\/2021\/6654168 (2021).","DOI":"10.1155\/2021\/6654168"},{"key":"27350_CR18","doi-asserted-by":"publisher","unstructured":"Virgili, G., Parravano, M., Evans, J. R., Gordon, I. & Lucenteforte, E. Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis. Cochrane Database Syst. Rev.. https:\/\/doi.org\/10.1002\/14651858.CD007419.PUB5 (2017).","DOI":"10.1002\/14651858.CD007419.PUB5"},{"key":"27350_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000459694","volume":"60","author":"L Mukkamala","year":"2017","unstructured":"Mukkamala, L., Bhagat, N. & Zarbin, M. Practical lessons from protocol T for the management of diabetic macular edema. Dev. Ophthalmol. 60, 109\u2013124. https:\/\/doi.org\/10.1159\/000459694 (2017).","journal-title":"Dev. Ophthalmol."},{"issue":"20","key":"27350_CR20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/JAMA.2015.15217","volume":"314","author":"JG Gross","year":"2015","unstructured":"Gross, J. G. et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 314(20), 2137\u20132146. https:\/\/doi.org\/10.1001\/JAMA.2015.15217 (2015).","journal-title":"JAMA"},{"key":"27350_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.AJO.2018.07.030","volume":"195","author":"NM Bressler","year":"2018","unstructured":"Bressler, N. M. et al. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. Am. J. Ophthalmol. 195, 93\u2013100. https:\/\/doi.org\/10.1016\/J.AJO.2018.07.030 (2018).","journal-title":"Am. J. Ophthalmol."},{"issue":"7","key":"27350_CR22","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/J.OPHTHA.2016.03.038","volume":"123","author":"RP Singh","year":"2016","unstructured":"Singh, R. P. et al. The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology 123(7), 1581\u20131587. https:\/\/doi.org\/10.1016\/J.OPHTHA.2016.03.038 (2016).","journal-title":"Ophthalmology"},{"key":"27350_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.AJO.2020.11.010","volume":"224","author":"JP Ehlers","year":"2021","unstructured":"Ehlers, J. P. et al. Retinal fluid volatility associated with interval tolerance and visual outcomes in diabetic macular edema in the VISTA phase III trial. Am. J. Ophthalmol. 224, 217\u2013227. https:\/\/doi.org\/10.1016\/J.AJO.2020.11.010 (2021).","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"27350_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/BJOPHTHALMOL-2016-310047","volume":"101","author":"JP Ehlers","year":"2017","unstructured":"Ehlers, J. P., Wang, K., Vasanji, A., Hu, M. & Srivastava, S. K. Automated quantitative characterisation of retinal vascular leakage and microaneurysms in ultra-widefield fluorescein angiography. Br. J. Ophthalmol. 101(6), 696\u2013699. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2016-310047 (2017).","journal-title":"Br. J. Ophthalmol."},{"key":"27350_CR25","doi-asserted-by":"publisher","unstructured":"Ehlers, J. P. et al. Compartmental exudative dynamics in neovascular age-related macular degeneration: Volumetric outcomes and impact of volatility in a phase III clinical trial. Ophthalmol retina. 8, 765\u2013777. https:\/\/doi.org\/10.1016\/J.ORET.2024.02.010 (2024).","DOI":"10.1016\/J.ORET.2024.02.010"},{"key":"27350_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000098495","volume":"39","author":"A Joussen","year":"2007","unstructured":"Joussen, A., Smyth, N. & Niessen, C. Pathophysiology of diabetic macular edema. Dev. Ophthalmol. 39, 1\u201312. https:\/\/doi.org\/10.1159\/000098495 (2007).","journal-title":"Dev. Ophthalmol."},{"issue":"7","key":"27350_CR27","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/J.OPHTHA.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das, A., McGuire, P. G. & Rangasamy, S. Diabetic macular edema: Pathophysiology and novel therapeutic targets. Ophthalmology 122(7), 1375\u20131394. https:\/\/doi.org\/10.1016\/J.OPHTHA.2015.03.024 (2015).","journal-title":"Ophthalmology"},{"issue":"13","key":"27350_CR28","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1167\/IOVS.16-19759","volume":"57","author":"M Mishra","year":"2016","unstructured":"Mishra, M. & Kowluru, R. A. The role of DNA methylation in the metabolic memory phenomenon associated with the continued progression of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 57(13), 5748\u20135757. https:\/\/doi.org\/10.1167\/IOVS.16-19759 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"27350_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/08820538.2021.1889620","volume":"36","author":"MJ Tsai","year":"2021","unstructured":"Tsai, M. J. & Cheng, C. K. Intravitreal aflibercept versus ranibizumab for diabetic macular edema in a Taiwanese health service setting. Semin Ophthalmol. 36(3), 132\u2013138. https:\/\/doi.org\/10.1080\/08820538.2021.1889620 (2021).","journal-title":"Semin Ophthalmol."},{"issue":"11","key":"27350_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun, J. K. et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 132(11), 1309\u20131316. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2350 (2014).","journal-title":"JAMA Ophthalmol."},{"issue":"3","key":"27350_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/DJO.DJO_13_17","volume":"18","author":"NMS El Gendy","year":"2017","unstructured":"El Gendy, N. M. S. Retinal ellipsoid zone\/external limiting membrane restoration after diabetic macular edema treatment. Delta J. Ophthalmol. 18(3), 160. https:\/\/doi.org\/10.4103\/DJO.DJO_13_17 (2017).","journal-title":"Delta J. Ophthalmol."},{"issue":"11","key":"27350_CR32","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0161-6420(80)35119-1","volume":"87","author":"JJ Weiter","year":"1980","unstructured":"Weiter, J. J. & Zuckerman, R. The influence of the photoreceptor-RPE complex on the inner retina: An explanation for the beneficial effects of photocoagulation. Ophthalmology 87(11), 1133\u20131139. https:\/\/doi.org\/10.1016\/S0161-6420(80)35119-1 (1980).","journal-title":"Ophthalmology"},{"issue":"1","key":"27350_CR33","doi-asserted-by":"publisher","first-page":"769213","DOI":"10.1155\/2014\/769213","volume":"2014","author":"YG Park","year":"2014","unstructured":"Park, Y. G., Kim, E. Y. & Roh, Y. J. Laser-Based strategies to treat diabetic macular edema: History and new promising therapies. J. Ophthalmol. 2014(1), 769213. https:\/\/doi.org\/10.1155\/2014\/769213 (2014).","journal-title":"J. Ophthalmol."},{"issue":"1","key":"27350_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/S00417-011-1774-X\/METRICS","volume":"250","author":"HJ Shin","year":"2012","unstructured":"Shin, H. J., Lee, S. H., Chung, H. & Kim, H. C. Association between photoreceptor integrity and visualoutcome in diabetic macular edema. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 250(1), 61\u201370. https:\/\/doi.org\/10.1007\/S00417-011-1774-X\/METRICS (2012).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"issue":"3","key":"27350_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/02713683.2015.1019003","volume":"41","author":"Y Shen","year":"2016","unstructured":"Shen, Y., Liu, K. & Xu, X. Correlation between visual function and photoreceptor integrity in diabetic macular edema: Spectral-domain optical coherence tomography. Curr. Eye Res. 41(3), 391\u2013399. https:\/\/doi.org\/10.3109\/02713683.2015.1019003 (2016).","journal-title":"Curr. Eye Res."},{"issue":"1","key":"27350_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/IAE.0B013E3181BD2C5A","volume":"30","author":"F Forooghian","year":"2010","unstructured":"Forooghian, F. et al. Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina 30(1), 63\u201370. https:\/\/doi.org\/10.1097\/IAE.0B013E3181BD2C5A (2010).","journal-title":"Retina"},{"issue":"1","key":"27350_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2010.01.039","volume":"150","author":"AS Maheshwary","year":"2010","unstructured":"Maheshwary, A. S. et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am. J. Ophthalmol. 150(1), 63\u201367. https:\/\/doi.org\/10.1016\/j.ajo.2010.01.039 (2010).","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"27350_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","volume":"38","author":"AR Santos","year":"2018","unstructured":"Santos, A. R. et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema. Retina 38(6), 1110\u20131119. https:\/\/doi.org\/10.1097\/IAE.0000000000001687 (2018).","journal-title":"Retina"},{"issue":"5","key":"27350_CR39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1097\/IAE.0B013E3181C2E0D6","volume":"30","author":"T Otani","year":"2010","unstructured":"Otani, T., Yamaguchi, Y. & Kishi, S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 30(5), 774\u2013780. https:\/\/doi.org\/10.1097\/IAE.0B013E3181C2E0D6 (2010).","journal-title":"Retina"},{"issue":"10","key":"27350_CR40","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown, D. M. et al. Intravitreal aflibercept for diabetic macular edema: 100-Week results from the VISTA and VIVID studies. Ophthalmology 122(10), 2044\u20132052. https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.017 (2015).","journal-title":"Ophthalmology"},{"issue":"11","key":"27350_CR41","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/S00417-022-05703-9\/FIGURES\/2","volume":"260","author":"M Sugimoto","year":"2022","unstructured":"Sugimoto, M., Handa, C., Hirano, K., Sunaya, T. & Kondo, M. Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-Month outcomes. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 260(11), 3489\u20133498. https:\/\/doi.org\/10.1007\/S00417-022-05703-9\/FIGURES\/2 (2022).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"issue":"6","key":"27350_CR42","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong, T. Y. et al. Faricimab Treat-and-Extend for diabetic macular edema: Two-Year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology 131(6), 708\u2013723. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026 (2024).","journal-title":"Ophthalmology"},{"issue":"10432","key":"27350_CR43","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown, D. M. et al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-Week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet 403(10432), 1153\u20131163. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1 (2024).","journal-title":"Lancet"},{"key":"27350_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ajo.2020.09.042","volume":"222","author":"P Osathanugrah","year":"2021","unstructured":"Osathanugrah, P. et al. The impact of race on short-term treatment response to bevacizumab in diabetic macular edema. Am. J. Ophthalmol. 222, 310\u2013317. https:\/\/doi.org\/10.1016\/j.ajo.2020.09.042 (2021).","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"27350_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/J.JNMA.2021.12.016","volume":"114","author":"N Sanjiv","year":"2022","unstructured":"Sanjiv, N. et al. Race and ethnic representation among clinical trials for diabetic retinopathy and diabetic macular edema within the united states: A review. J. Natl. Med. Assoc. 114(2), 123\u2013140. https:\/\/doi.org\/10.1016\/J.JNMA.2021.12.016 (2022).","journal-title":"J. Natl. Med. Assoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27350-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27350-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27350-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T09:51:44Z","timestamp":1764928304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27350-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27350"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27350-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KM: None; AI: None; SY: None; HC: None; JLR: None; SKS: Research support: Regeneron, Allergan, and Gilead; Consultant: Bausch and Lomb, Adverum, Novartis, and Regeneron; Patent: Leica; JPE: Consultant: Zeiss, Leica\/Bioptigen, Alcon, Beyeonics. Allergan, Allegro, Adverum, Regeneron, Roche, Genentech, RegenxBIO, Iveric Bio, Boehringer Ingelheim, Apellis, Novartis, Boehringer Ingelheim, Stealth Biotherapeutics, Perceive Biotherapeutics, Exegenesis, Ophthalytics, Eyepoint, Abbvie, Bayer, BVI, Alexion, Ocular Therapeutix; Research grants: Regeneron, Genentech, Oxurion\/Thrombogenics, Alcon, Aerpio, Allergan, Roche, Iveric Bio, Boehringer Ingelheim, Adverum, Novartis, Zeiss, Stealth Biotherapeutics, Perceive Biotherapeutics, Alexion, Beyeonics, Ocular Therapeutix.; Patents\/Intellectual Property\/Licensing: Bioptigen\/Leica.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43222"}}